Objective: To quantify the association between vulvovaginal atrophy and depression, major depressive disorder, and anxiety.
Methods: Women with vulvovaginal atrophy from the Truven Health MarketScan Commercial and Medicare Supplemental Databases (01/2010-09/2016) with ≥365 days of continuous insurance coverage before and after the first vulvovaginal atrophy/dyspareunia diagnosis (index date) were selected. Women with vulvovaginal atrophy were matched 1:3 to women without (controls) according to age, calendar year, health plan, and region. The study period spanned from 12 months before to 12 months after index date. The ratios of diagnosed depression, major depressive disorder, and anxiety among women with vulvovaginal atrophy and the controls were calculated. Logistic regressions adjusting for proxies of menopause were used to compare prevalence.
Results: In all, 125,889 women with vulvovaginal atrophy and 376,057 controls were included (mean age 60.7 [45-101]). The prevalence of depression, major depressive disorder, and anxiety was higher among women with vulvovaginal atrophy compared with controls (23.9% vs 18.9%, 6.3% vs 4.7%, 16.6% vs 11.3%), with prevalence ratios of 1.26, 1.33, and 1.47, respectively (all P < 0.0001). Highest prevalences and differences were observed in younger women. Findings were consistent when analyzing newly diagnosed conditions. When adjusting for proxies of menopause (insomnia, vasomotor symptoms, dysuria, and estrogen therapy), vulvovaginal atrophy remained significant (prevalence odds ratios; depression 1.23, major depressive disorder 1.22, anxiety 1.39; all P < 0.0001).
Conclusions: Vulvovaginal atrophy is associated with a significantly higher prevalence/incidence of depression, major depressive disorder, and anxiety. The higher prevalence/incidence and greater differences in younger women highlight the need for a multidisciplinary approach and early diagnosis/management of vulvovaginal atrophy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/GME.0000000000001450 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of vaginal estrogen on serum estradiol during aromatase inhibitor therapy in breast cancer patients with vulvovaginal atrophy: a prospective trial.
Breast Cancer Res Treat
December 2024
Comprehensive Cancer Center, Helsinki University Hospital, University of Helsinki, PO Box 180, 00290, Helsinki, Finland.
Purpose: This study aimed to analyze changes in serum estradiol (E2) levels during concurrent vaginal estradiol therapy and adjuvant letrozole in postmenopausal breast cancer (BC) patients with vulvovaginal atrophy (VVA). Secondary objectives included assessing the effects of therapy on vaginal atrophy, quality of life (QoL) and menopause-related symptoms.
Methods: 20 postmenopausal patients undergoing adjuvant letrozole therapy and experiencing VVA symptoms were treated with vaginal estradiol for 12 weeks.
Hysterectomy without oophorectomy as a risk factor for genitourinary syndrome of menopause.
Int J Gynaecol Obstet
December 2024
Department of Menopause, Instituto Nacional de Perinatología, Mexico City, Mexico.
Anxiety and Depression in Japanese Patients with Genitourinary Syndrome of Menopause.
Int Urogynecol J
December 2024
Department of Obstetrics and Gynecology, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Chiba, Japan.
Introduction And Hypothesis: Women with genitourinary syndrome of menopause (GSM) may have anxiety and depression; however, this is unclear.
Methods: A total of 646 postmenopausal women undergoing treatment for menopausal symptoms were enrolled in this retrospective cross-sectional study. Questionnaire responses were recorded at the first visit, and participants were divided into GSM (≥1 moderate or severe GSM symptom) or no-GSM (without any moderate/severe symptoms) groups.
Photobiomodulation in post menopause genitourinary syndrome-Study protocol for a randomized, double-blind, controlled clinical protocol.
PLoS One
December 2024
Post Graduation Program in Biophotonics Medicine, Universidade Nove de Julho, São Paulo, SP, Brazil.
Introduction: Genitourinary Syndrome of Menopause (GSM) defines a set of symptoms associated with an estrogen deficit involving alterations in organs genitourinary and that results in several urinary, genital, and sexual alterations. Brazilian women live about a third of their life after menopause, where hormonal changes occur along with clinical manifestations, characterized by vaginal and vulvar dryness, burning sensation, discomfort, vulvovaginal irritation, lack of lubrication, dyspareunia and urinary incontinence. Fractionated photothermolysis and radiofrequency systems, alone or in combination were tested to improve GSM.
View Article and Find Full Text PDFUpdate on Genitourinary Syndrome of Menopause: A Scoping Review of a Tailored Treatment-Based Approach.
Life (Basel)
November 2024
Department of Medical and Surgical Sciences and Translational Medicine, PhD Course in "Translational Medicine and Oncology", Sapienza University of Rome, Viale dell'Università, 37, 00185 Rome, Italy.
Article Synopsis
- This scoping review examines treatment options for genitourinary syndrome of menopause (GSM), a commonly overlooked condition caused by reduced estrogen levels during menopause, leading to various symptoms impacting women's quality of life.
- The review analyzed 451 articles and ultimately included 19 studies that highlight first-line treatments like lubricants and moisturizers, as well as hormonal therapies such as selective estrogen receptor modulators and DHEA for managing severe symptoms.
- It emphasizes the importance of tailored therapy and effective communication to help women make informed treatment choices while calling for more research into GSM therapies, especially concerning safety in women with cancer histories.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!